New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas.
Cheson
B D
BD
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892.
D000477:Alkylating Agents / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047630:Depsipeptides; D005708:Gallium / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008935:Mitoguazone / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D013498:Suramin / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins; D013498:Suramin; D005708:Gallium; D008935:Mitoguazone; D017239:Paclitaxel; C027235:gallium nitrate